乳腺癌易感基因研究进展

Ｂｒｃａｌ和Ｂｒｃａ２是乳腺癌易感基因,在家族性乳腺癌患者中的突变是可以遗传的,在散发性乳腺癌患者中有杂合性丢失（ＬＯＨ）,而且表达水平下降,体外实验证明,Ｂｒｃａｌ能抑制乳腺癌和卵巢癌细胞的的增殖。Ｂｒｃａｌ和Ｂｒｃａ２基因分别定位于１７ｑ１２－２１和１３ｑ１２－１３,编码序列５７１１ｂｐ和１０９８７ｂｐ,其表达有一定的组织特异性。ＢＲＣＡ１和ＢＲＣＡ２蛋白分别由１８６３个氨基酸和３４１８个氨基     

BRCA1基因结构及其在乳腺癌中的表达

利用ＭＰＣＲ技术从乳腺组织分离到抑癌基因ＢＲＣＡ１的ｃＤＮＡ片段,将此９１４ｂｐ的片段克隆进质粒ｐＵＣ１１８,并经全序列测定证实。序列分析表明,ＢＲＣＡＩｃＤＮＡ编码的肽链ＮＮ２－末端有一锌指结构,抑癌基因ＢＲＣＡＩ的产物可能是ＤＮＡ结合蛋白,ｃＤＮＡ序列存在两个变异位点：一个是第４０９位的Ｃ→Ａ（Ａｓｐ→Ｇｌｕ）：另一个是第８７９位的Ａ→Ｔ（ＭＩａ同义突变）。以该片段为探针,检测６例乳腺癌组织中ＢＲＣＡＩｍＩＭＡ表达,一例表达明显下降,一例没检测到表达的ｍＩＭＡ产物,说明一些乳腺癌组织的ＢＲＣＡ１基因转录水平降低     

抗真菌蛋白Rs—AFPs基因在大肠杆菌中的表达

将抗真菌蛋白Ｒｓ－ＡＦＰ１和Ｒｓ－ＡＦＰ２全长ｃＤＮＡ插入表达质粒ｐＥＴ－２２ｂ／ＮｃｏＩ＋ＳａｃＩ位点,构建成融合蛋白表达载体ｐＲＡＦ１和ｐＲＡＦ２．将不含信号肽编码序列的Ｒｓ－ＡＦＰ１和Ｒｓ－ＡＦＰ２ｃＤＮＡ分别插入ｐＥＴ－２２ｂ／Ｎｃｏｌ＋Ｓａｃｌ和ｐＥＴ－２２ｂ／Ｎｄｅｌ＋ＳａｃＩ位点,构建成不含信号肽序列的融合蛋白表达载体ｐＲＡＦ３、ｐＲＡＦ４和非融合蛋白表达载体ｐＲＡＦ５和ｐＲＡＦ６．将构建的上述各种表达载体转化Ｅ．ｃｏｌｉＢＬ２１,挑菌落培养,ＩＰＴＧ诱导,使Ｒｓ－ＡＦＰｓ基因得到表达,并用体外抑菌试验检测表达产物的活性,结果表明,各种表达载体的表达产物均具有不同程度的抑菌活性,其中,ｐＲＡＦ３和ｐＲＡＦ４表达产物的抑菌活性较明显．     

丝瓜的三聚体G蛋白的初步研究

根据拟南芥（ａｒａｂｉｄｏｐｓｉｓｔｈａｈｌｉａｎａ）ＧＰＡ１的保守区段Ａ设计一对特异引物（５′ｃｔｇｇｇｇａａｔｃｔｇｇａａａａｔｃ３′,５′ｃａｃａｇｃｔｇｔａｃａｃｃｔｃａａａｃ３′）通过ＰＣＲ从丝瓜核基因组中扩增植物的三聚体Ｇ蛋白α亚基编码基因,获得了２个片段（ＬＦＧ１,ＬＦＧ２）,并已克隆和测序（已在ＥＭＢＬ数据库中登记,登记号为：ｙ１５２７０,ｙ１５２７１）．序列分析表明ＬＦＧ１和ＬＦＧ２分别由１５１５ｂｐ和７３２ｂｐ构成,都含有三聚体Ｇ蛋白α亚基编码基因的保守区段Ａ,但也都含有内含子．根据片段的大小及ＰＣＲ的特性,ＬＦＧ１可能是丝瓜三聚体Ｇ蛋白α亚基编码基因上的片段．     

传染性法氏囊病病毒中国强毒株A节段cDNA基因的克隆和序列分析

以来自哈尔滨传染性法氏囊病病毒（ＩＢＤＶ） 强毒株（Ｈａｒｂｉｎ 毒株,Ｈ） 的基因组ＲＮＡ为模板,用反转录聚合酶链反应（ＲＴ－ ＰＣＲ） 的方法得到了其Ａ 节段的全长ｃＤＮＡ 片段,分５＇端（１ ６５９ｂｐ） 和３＇端（１ ４４４ｂｐ） 上下两段分别克隆到ｐＧＥＭＢ○Ｒ － Ｔ 载体上,测定了其核苷酸顺序,在长为３ １０１ ｂｐ 中含有两个阅读框ＯＲＦＡ１ 和ＯＲＦＡ２ ,分别编码１ ０１２ 个氨基酸的前体蛋白（ＶＰ２ － ４ －３） 和１４５ 个氨基酸的ＶＰ５,ＯＲＦＡ１ 和ＯＲＦＡ２ 有部分的重叠。将核苷酸序列及推测出的氨基酸序列与已报道的ＩＢＤＶ 血清Ⅰ型和Ⅱ型毒株的相应序列进行了比较,结果表明：Ｈ 毒株与其它血清Ⅰ型毒株之间,在核苷酸水平上存在２５ｂｐ － ２６７ｂｐ 的差异;在氨基酸水平上存在１７ ～４０ 个氨基酸的差异。在ＶＰ２ － ４ － ３ 内比较显示,Ｈ 毒株与Ｐ２ 、Ｃｕ－ １ 之间氨基酸的差异最小为１ ．７％ ,Ｈ 毒株与ＵＫ６６１ 之间氨基酸的差异最大为３ ．９ ％ 。变异主要发生在ＶＰ２ 的可变区（２０６ － ３５０ 位氨基酸） ,在Ｈ 毒株所特有的１２ 个氨基酸当中,该区就占５ 个,代表１ ．７６ ％ 的变异。ＶＰ４、ＶＰ３ 和ＶＰ５区各有     

抗癌胚抗原单链抗体基因在家蚕细胞和幼虫中的表达

将抗癌胚抗原（ＣＥＡ）单链抗体基因插入家蚕杆状病毒转移载体ｐＢａｃＰＡＫＨｉｓ, 与修饰的家蚕核型多角体病毒ＢｍＢａｃＰＡＫＤＮＡ共转染家蚕细胞, 经同源重组得到含有在多角体蛋白基因启动子控制下的抗ＣＥＡＳｃＦｖ 基因的重组病毒ＢｍＢａｃＳｃＦｖ。用重组病毒分别感染家蚕细胞和幼虫, 在两者中均得到了高效表达, 产物分子量为２８ｋＤ, 前者占细胞总蛋白的６ ％ , 后者为０ ．３ ｍｇ／ 蚕。目的基因在家蚕细胞和幼虫中表达产物经Ｎｉ２＋ＩＤＡＳｅｐｈａｒｏｓｅ６Ｂ亲和柱纯化, 前者纯度可达９０％ 以上, 后者纯度较低; 纯化后的融合蛋白具有ＣＥＡ 结合活力, 其亲和常数分别为５ ．４×１０８／ｍｏｌ·Ｌ－ １ 和２．３ ×１０８／ｍｏｌ·Ｌ－１ , 略低于其亲本单抗Ｅ７Ｂ１０ ２．７ ×１０９／ｍｏｌ·Ｌ－ １ 。     

阴沟肠杆菌(nifL－Ac)工程菌株的构建

采用基因定位突变的方法,在体外把来自ｐＢＲ３２２ 的四环素抗性（Ｔｃｒ） 基因片段插入由ｐＳＴ１１４２ 质粒所携带的阴沟肠杆菌ｎｉｆＬ基因３’端的Ｓｍａ Ⅰ位点,再经细胞体内同源基因片段的重组交换,选择获得了在染色体上ｎｉｆＬ突变的阴沟肠杆菌Ｅ１２ 和Ｅ１３ ,两者Ｔｃｒ 基因插入ｎｉｆＬ的转录方向相反。经分析显示,Ｅ１３（ ｎｉｆＬ－ ） 由于Ｔｃｒ 基因插入后,在ｎｉｆＡ上游产生具有启动子功能的核苷酸序列（ＴＴＴＣＡＴＡ） ,激活ｎｉｆＡ 的表达。当Ｅ１３ 和Ｅ１２ 被引入多拷贝组成型ｎｉｆＡ 质粒ｐＢＦ１０１后,在有氨条件下ｎｉｆ 基因去阻遏表达,呈高的固氮酶活力,与野生型Ｅ２６（ｐＢＦ１０１） 比较,其比活力提高近１ 倍     

HCV核心蛋白免疫优势肽AA32—45抗原化抗体的构建

经定点突变,在抗ＨＢｓＡｇ单克隆抗体重链Ｖ区产生一个ＸｈｏＩ位点并插入编码ＨＣＶ核心蛋白免疫优势肽ＡＡ３２￣４５的互补寡核苷酸片段,构成抗原化ＶＨ基因。抗原化ＶＨ与人γ３恒区ｃＤＮＡ拼接成嵌合重链基因并与嵌合轻链基因共同构建成杆状病毒表达系统转移载体,经共转染筛选到重组病毒ＢａｃＨＬ－Ｅ１和ＢａｃＨＬ－Ｅ２,感染Ｓｆ９细胞分别表达Ｉｇ－Ｅ１和Ｉｇ－Ｅ２。Ｉｇ－Ｅ１与正常免疫球蛋白分子一样能形成四聚     

传染性法氏囊病病毒中国强毒株节段cDNA基因的克隆和序列分析

以来自哈尔滨传染性法氏囊病病毒（ＩＢＤＶ）强素株（Ｈａｒｂｉｎ 毒株,Ｈ）的基因组ＲＮＡ为模板,用反转录聚合酶链反应（ＲＰ－ＰＣＲ）的方法得到了其Ａ节段的全长ｃＤＮＡ片段,分５端（１６５９ｂｐ）和３端（１４４４ｂｐ）上下两段分别克隆到ｐＧＥＭＢ－Ｔ载体上,测定了其核苷酸顺序,在长为３１０１ｂｐ中含有两个阅读枢ＯＲＦ Ａ１和ＯＲＦ Ａ２,分别编码１０１２个氨酸酸的前体蛋白（ＶＰ２－４－３）和１４５个     

人肝癌中的抑癌基因

杂合性丢失分析资料显示,在肝癌的发生和演进过程中涉及多种抑癌基因失活。国内外研究表明,肝癌中存在抑癌基因ＴＰ５３突变失活,ＴＰ５３基因突变表现特异性和病因相关性。作者通过检查１５个高度多态的微卫星标记,进行染色体缺失精细定位,将肝癌中染色体１３ｑ缺失的最小重叠区域限定于１３ｑ１４,强烈提示ＲＢ１基因为染色体缺失的靶基因;进一步应用ＰＣＲ－ＳＳＣＰ分析和ＤＮＡ测序发现２例发生染色体１３ｑ臂内缺失的肝癌中有ＲＢ１基因微小缺失,其结果是无法编码有功能的蛋白产物,从而找到肝癌中ＲＢ１基因失活的可靠证据;免疫组织化学染色表明,５２％的肝癌组织中ｐ１１０ＲＢ１蛋白丢失且与染色体１３ｑ杂合性丢失高度相关。因此,确定ＲＢ１基因为肝癌的又一重要抑癌基因。     

The Human Lamin B Receptor/Sterol Reductase Multigene Family

LBR (lamin B receptor) is an integral protein of the inner nuclear membrane encoded by a gene on human chromosome 1q42.1. LBR has a nucleoplasmic, amino-terminal domain of approximately 200 amino acids followed by a carboxyl-terminal domain similar in sequence to yeast and plant sterol reductases. We have determined the primary structures of two human proteins with strong sequence similarity to the carboxyl-terminal domain of LBR and sterol reductases. Their genes have recently been assigned the symbols TM7SF2 and DHCR7. TM7SF2 mRNA is most predominantly expressed in heart and DHCR7 mRNA mostly in liver and brain. Whereas LBR is localized to the inner nuclear membrane, these two related proteins are in the endoplasmic reticulum. TheTM7SF2gene contains 10 coding exons, and its intron positions are exactly conserved in the part of theLBRgene encoding its carboxyl-terminal domain. Intron positions in theDHCR7gene are also similar. Both of these new LBR-like genes are on chromosome 11q13. These results describe a human gene family encoding proteins of the inner nuclear membrane and endoplasmic reticulum that function in nuclear organization and/or sterol metabolism.     

Chromosomal mapping of human adenylyl cyclase genes type III,type V and type VI

Adenylyl cyclase activity plays a central role in the regulation of most cellular processes. At least eight different adenylyl cyclases have been identified, which are endowed with various and sometimes opposing regulatory properties. Recently we have localized the human genes encoding two of these adenylyl cyclases: the gene for type 11 adenylyl cyclase is located on chromosome 2 (sub-band 2p15.3), the gene for type VIII is located on chromosome 8 (sub-band 8824.2). More recently the type I gene has been located on chromosome 7 (sub-band 7pl2–7p13). Using in situ hybridization, we have now localized the genes for three other adenylyl cyclases: the type III gene has been localized on chromosome 2 in the sub-band 2p22–2p24, the type V gene on chromosome 3 at position 3q13.2–3q21, and the type VI gene on chromosome 12 at position 12q12–12q13. It therefore appears that all adenylyl cyclase genes, known at present are located on different chromosomes and thus are likely to be independently regulated.     

Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene

We have isolated and sequenced part of a new gene of the tyrosine kinase family. This gene, called FLT3, has strong sequence similarities with members of a group of genes encoding growth factor receptors: FMS, KIT, and PDGFR. We have localized the human FLT3 gene to chromosome 13, band q12, and its mouse homolog to chromosome 5, region G.     

Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination

The breast cancer susceptibility protein, Brca2 and the RecQ helicase, Blm (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through homologous recombination (HR). Brca2 facilitates HR by interacting with Rad51 in multiple regions, the BRC motifs encoded by exon 11 and a single domain encoded by exon 27; however, the exact importance of these regions is not fully understood. Blm also interacts with Rad51 and appears to suppress HR in most circumstances; however, its yeast homologue Sgs1 facilitates HR in response to some genotoxins. To better understand the biological importance of these two proteins, we performed a genotoxic screen on mouse embryonic stem (ES) cells impaired for either Brca2 or Blm to establish their genotoxic profiles (a cellular dose-response to a wide range of agents). This is the first side-by-side comparison of these two proteins in an identical genetic background. We compared cells deleted for Brca2 exon 27 to cells reduced for Blm expression and find that the Brca2- and Blm-impaired cells exhibit genotoxic profiles that reflect opposing activities during HR. Cells deleted for Brca2 exon 27 are hypersensitive to γ-radiation, streptonigrin, mitomycin C and camptothecin and mildly resistant to ICRF-193 which is similar to HR defective cells null for Rad54. By contrast, Blm-impaired cells are hypersensitive to ICRF-193, mildly resistant to camptothecin and mitomycin C and more strongly resistant to hydroxyurea. These divergent profiles support the notion that Brca2 and Blm perform opposing functions during HR in mouse ES cells.     

Exclusion of the retinoblastoma gene and chromosome 13q as the site of a primary lesion for human breast cancer.

Chromosome 13q has been suggested as the site of a gene predisposing to human breast cancer, because loss of heterozygosity of alleles on this chromosome has been observed in some ductal breast tumors and because two breast cancer lines are altered at the retinoblastoma gene (RB1) at 13q14. To test this possibility, linkage of breast cancer susceptibility to 14 loci on chromosome 13q loci was assessed in extended families in which breast cancer is apparently inherited as an autosomal dominant trait. RB1 was excluded as the site of a breast cancer gene by a lod score of Z = -7.60 at close linkage for 13 families. Multipoint analysis yielded negative lod scores throughout the region between 13q12 and 13q34; over most of this distance, Z less than -2.0. Therefore, chromosome 13q appears to be excluded as the site of primary lesion for breast cancer in these families. In addition, comparison of tumor versus normal tissues of nonfamilial breast cancer patients revealed an alteration at the 5' end of RB1 in a mucoid carcinoma but no alterations of RB1 in five informative ductal adenocarcinomas. Linkage data and comparisons of tumor and normal tissues suggest that changes in the RBI locus either are secondary alterations associated with progression of some tumors or occur by chance.     

Interaction of p14ARF with Brca1 in cancer cell lines and primary breast cancer

We report an association between p14ARF and Brca1 in which both proteins co-immunoprecipitate (co-IP) in DU145 cells. The N-terminal 64 residues of p14ARF encoded by exon 1beta are sufficient for this association. Inside the cell, ectopic p14ARF co-localizes with ectopic and endogenous Brca1 in A375 cells. Endogenous p14ARF co-localizes with endogenous Brca1 in DU145 cells but not in H1299 cells. Since p14ARF interacts with B23 in the nucleolus, Brca1 co-localizes with B23 in DU145 but not in H1299 cells. While ectopic ARF potently inhibited DU145 cell proliferation, it had no effect on the proliferation of H1299 cells, suggesting that the interaction between ARF and Brca1 contributes to ARF-mediated tumor suppression. Consistent with this notion, ectopic p14ARF modulates endogenous Brca1 expression in MCF7 breast cancer cells and p14ARF co-localizes with Brca1 in normal breast epithelial cells. This co-localization is enhanced in primary breast cancer. Taken together, the results show that p14ARF associates with Brca1, which may play a major role in tumor suppression.     

The GABAA receptor beta 3 subunit gene: characterization of a human cDNA from chromosome 15q11q13 and mapping to a region of conserved synteny on mouse chromosome 7.

A cDNA encoding the human GABAA receptor beta 3 subunit has been isolated from a brain cDNA library and its nucleotide sequence has been determined. This gene, GABRB3, has recently been mapped to human chromosome 15q11q13, the region deleted in Angelman and Prader-Willi syndromes. The association of distinct phenotypes with maternal versus paternal deletions of this region suggests that one or more genes in this region show parental-origin-dependent expression (genetic imprinting). Comparison of the inferred human beta 3 subunit amino acid sequence with beta 3 subunit sequences from rat, cow, and chicken shows a very high degree of evolutionary conservation. We have used this cDNA to map the mouse beta 3 subunit gene, Gabrb-3, in recombinant inbred strains. The gene is located on mouse chromosome 7, very closely linked to Xmv-33 between Tam-1 and Mtv-1, where two other genes from human 15q11q13 have also been mapped. This provides further evidence for a region of conserved synteny between human chromosome 15q11q13 and mouse chromosome 7. Proximal and distal regions of mouse chromosome 7 show genetic imprinting effects; however, the region of homology with human chromosome 15q11q13 has not yet been associated with these effects.     

The human and mouse replication-dependent histone genes

The multigene family encoding the five classes of replication-dependent histones has been identified from the human and mouse genome sequence. The large cluster of histone genes, HIST1, on human chromosome 6 (6p21-p22) contains 55 histone genes, and Hist1 on mouse chromosome 13 contains 51 histone genes. There are two smaller clusters on human chromosome 1: HIST2 (at 1q21), which contains six genes, and HIST3 (at 1q42), which contains three histone genes. Orthologous Hist2 and Hist3 clusters are present on mouse chromosomes 3 and 11, respectively. The organization of the human and mouse histone genes in the HIST1 cluster is essentially identical. All of the histone H1 genes are in HIST1, which is spread over about 2 Mb. There are two large gaps (>250 kb each) within this cluster where there are no histone genes, but many other genes. Each of the histone genes encodes an mRNA that ends in a stemloop followed by a purine-rich region that is complementary to the 5' end of U7 snRNA. In addition to the histone genes on these clusters, only two other genes containing the stem-loop sequence were identified, a histone H4 gene on human chromosome 12 (mouse chromosome 6) and the previously described H2a.X gene located on human chromosome 11. Each of the 14 histone H4 genes encodes the same protein, and there are only three histone H3 proteins encoded by the 12 histone H3 genes in each species. In contrast, both the mouse and human H2a and H2b proteins consist of at least 10 non-allelic variants, making the complexity of the histone protein complement significantly greater than previously thought.